The global radiopharmaceutical CDMO market is expected to post strong growth through 2034, with DelveInsight projecting an annual growth rate of about 10%. The outlook reflects rising activity across the radiopharmaceutical sector, especially as more targeted radiotherapies and radiodiagnostic products move through development and toward wider commercial use.
Contract development and manufacturing organizations are becoming increasingly important in this market because radiopharmaceutical production requires highly specialized facilities, technical expertise, and strict handling standards. As the pipeline expands, drug developers are looking for partners that can support complex manufacturing needs while helping maintain quality and regulatory compliance.
Another major factor behind the market’s momentum is the combination of clinical progress and commercial scaling. Companies working on targeted radioactive medicines and imaging agents often need outside manufacturing support to manage development timelines, regulatory demands, and reliable supply. That dynamic is helping push more outsourcing activity toward dedicated radiopharmaceutical CDMOs.
Overall, the report points to a favorable long-term outlook for the radiopharmaceutical CDMO market. Growth is being supported by the broader adoption of precision nuclear medicine, the need for specialized production capabilities, and increasing pressure on developers to bring advanced radiopharmaceutical products to market efficiently.
